Epicrispr Raises $90M for Epigenetic FSHD Therapy

Epicrispr Biotechnologies has successfully closed a substantial $90 million Series C funding round, signaling strong investor confidence in its pioneering epigenetic approach to treating facioscapulohumeral muscular dystrophy (FSHD). This significant capital infusion is earmarked to propel the company's lead candidate, EPI-321, into pivotal clinical trials, marking a critical advancement for a disease with no current disease-modifying therapies.

The financing was co-led by Octagon Capital and Janus Henderson Investors, with robust participation from a distinguished syndicate including Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn, Angelini Ventures, Readout Capital, and existing investors. The oversubscribed round underscores the growing interest in gene expression modulation technologies that offer alternatives to traditional gene editing.

FSHD, a progressive inherited disorder affecting approximately 80,000 individuals in the U.S., is characterized by the inappropriate reactivation of the DUX4 gene in adult muscle tissue, leading to cellular degeneration. Unlike conventional gene therapies that alter the DNA sequence, Epicrispr's proprietary Gene Expression Modulation System (GEMS) selectively silences the DUX4 gene without making permanent changes to the genetic code. This innovative strategy leverages a compact Cas protein, enabling efficient delivery via a single adeno-associated virus (AAV) vector.

Encouraging interim data from the Phase 1/2 study of EPI-321 has been a key catalyst for this funding. Early results from three evaluable patients demonstrated a notable average increase in whole-body lean muscle volume of approximately 370 mL, alongside favorable biomarker changes indicating DUX4 suppression and improvements in strength and function. These findings represent the first clinical evidence of muscle regeneration in FSHD patients, a significant development in a field historically focused on managing decline.

The strategic shift in the investor base, with a notable influx of crossover and hedge funds, suggests a maturing company poised for later-stage development and potential public market readiness. This Series C follows previous funding rounds, including a $55 million Series A in July 2022 led by Horizons Ventures and a $68 million Series B in March 2025, co-led by Ally Bridge Group and supported by SOLVE FSHD. The cumulative funding now stands at over $213 million.

Amber Salzman, CEO of Epicrispr, highlighted the significance of the financing, stating, "This positions us to advance EPI-321 into pivotal studies, expand our pipeline, and continue building a new class of epigenetic therapies for patients." The company's platform, co-developed by Stanford bioengineer Stanley Qi, represents a significant leap in precision medicine, offering a potentially transformative treatment paradigm for genetic disorders where gene expression, rather than sequence integrity, is the primary issue. The market for rare genetic diseases continues to attract substantial investment, driven by unmet medical needs and the potential for breakthrough therapies.